One year after his arrest as one of three men charged over the murder of Daphne Caruana Galizia, George Degiorgio has filed a judicial letter against the prison director claiming he was a victim of inhuman and degrading treatment.

Mr Degiorgio, who alongside his brother Alfred and Vincent Muscat, is currently facing criminal proceedings over the trio’s alleged involvement in the car bomb that killed the journalist on October 16, 2017, has called upon the Prison Director to make necessary arrangements for medical care because of his "painful" condition.

All three have been under preventive arrest since being targeted during a police raid in Marsa one year ago today.

Lawyer explained that for months, accused has been suffering from “persistent and unbearable pain” in his shoulder while in custody

Mr Degiorgio’s lawyer, William Cuschieri, explained that his client had, for months, been suffering from “persistent and unbearable pain” in his shoulder while in custody.

On November 14, the Criminal Court heard the prison director declare that he would be arranging a private clinic appointment for the inmate at the latter's expense.

But no steps had been taken except for painkillers being administered to the accused. These only served to mask the pain briefly, Dr Cuschieri claimed “and in no way constituted the care required”.

Claiming that the director was “passive” by failing to ensure that Mr Degiorgio was medically examined and treated while under his care, Dr Cuschieri said this amounted to inhuman and degrading treatment.

Tuesday’s act is one of several constitutional cases filed by the men accused of the murder since their arrest.

In September, George Degiorgio had filed a constitutional application claiming to be the victim of a frame up for the murder, with the police seeking to find evidence to justify his detention after his arrest.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.